---
title: "Pralmorelin (GHRP-2)"
canonical_url: https://peptidelibrary.app/library/pralmorelin-ghrp2
description: "Pralmorelin is GHRP-2, used as a GH-stimulation diagnostic in Japan. Research vials are not that approved diagnostic. WADA S2 names GHRP-2 (pralmorelin)."
updated: 2026-09-06
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Pralmorelin (GHRP-2)

Pralmorelin (GHRP-2), also called KP-102 or GPA 748, is a diagnostic GH secretagogue in the Growth Hormone Secretagogue class. Pralmorelin, also called GHRP-2, is a synthetic agonist at growth hormone secretagogue receptor 1a that produces potent growth hormone release through combined direct pituitary stimulation and reduced hypothalamic somatostatin tone.

Pralmorelin is GHRP-2, used as a GH-stimulation diagnostic in Japan. Research vials are not that approved diagnostic. WADA S2 names GHRP-2 (pralmorelin).

Also known as: KP-102, GPA 748.

Categories: Fat Loss, Muscle/Recovery, Experimental.

## Classification

- Type: GHRP-2 / diagnostic GH secretagogue
- Mechanism class: Growth Hormone Secretagogue
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Pralmorelin, also called GHRP-2, is a synthetic agonist at growth hormone secretagogue receptor 1a that produces potent growth hormone release through combined direct pituitary stimulation and reduced hypothalamic somatostatin tone. It is more potent than GHRP-6 at releasing growth hormone but retains meaningful activity on the corticotroph axis, commonly raising ACTH and cortisol, and it stimulates appetite. It has an approved diagnostic use in Japan as an intravenous test of growth hormone secretory reserve; that single-dose diagnostic context is pharmacologically distinct from the repeated subcutaneous research use for which it is sold elsewhere.

Targets: GHSR.

Origin: Synthetic hexapeptide GHRP.

## Properties

- Molecular formula: C45H55N9O6
- Molecular weight: 801.98 g/mol
- CAS number: 158861-67-7
- Half-life: Reported short; human diagnostic use in Japan
- Studied routes: Intravenous

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Early or uncontrolled human studies
- Human trials: 2
- Controlled human trials: 0
- Preclinical sources: 0
- Latest source: 2013

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. GH-releasing peptide-2 does not stimulate arginine vasopressin secretion in healthy men. Endocr J. 2010. 2010. Human study (early or uncontrolled). Population: 10 healthy men, fasting and non-fasting. ACTH, GH, FSH, LH, prolactin, TSH and vasopressin responses [Source](https://pubmed.ncbi.nlm.nih.gov/19907099/)
2. The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients. Endocr J. 2013. 2013. Human study (early or uncontrolled). Population: 71 pre-operative adults with pituitary tumours, aged 18-65. Diagnosis of adult growth hormone deficiency versus the insulin tolerance test [Source](https://pubmed.ncbi.nlm.nih.gov/23079545/)
3. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN. Drugs R D. 2004. 2004. Secondary report (review or programme summary), not a trial. Population: Development-stage summary. Development status of GHRP-2 / KP-102. Limitations: Reported in research, not a controlled trial. [Source](https://pubmed.ncbi.nlm.nih.gov/15230633/)

## Safety

Side effects: Hunger; Cortisol rise; Flushing.

Risks: WADA S2.

Human safety basis: Limited human reports

Key limitations: No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Pralmorelin (GHRP-2) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is Pralmorelin (GHRP-2)?

Pralmorelin is GHRP-2, used as a GH-stimulation diagnostic in Japan. Research vials are not that approved diagnostic. WADA S2 names GHRP-2 (pralmorelin).

### How does Pralmorelin (GHRP-2) work?

Pralmorelin, also called GHRP-2, is a synthetic agonist at growth hormone secretagogue receptor 1a that produces potent growth hormone release through combined direct pituitary stimulation and reduced hypothalamic somatostatin tone. It is more potent than GHRP-6 at releasing growth hormone but retains meaningful activity on the corticotroph axis, commonly raising ACTH and cortisol, and it stimulates appetite.

### Is Pralmorelin (GHRP-2) FDA approved?

No. Pralmorelin (GHRP-2) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A Category 3: Nominated without adequate support; 503B Category 2: FDA identified significant safety risks (injectable and nasal routes).

### What is the half-life of Pralmorelin (GHRP-2)?

Reported half-life for Pralmorelin (GHRP-2) is Reported short; human diagnostic use in Japan. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Pralmorelin (GHRP-2) banned in sport?

Pralmorelin (GHRP-2) is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to Pralmorelin (GHRP-2)?

Compounds most often compared with Pralmorelin (GHRP-2) include Ipamorelin, GHRP-6, GHRP-1 and Hexarelin (Examorelin). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN — Drugs R D, 2004](https://pubmed.ncbi.nlm.nih.gov/15230633/)
- [Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial — Drug Test Anal, 2019](https://pubmed.ncbi.nlm.nih.gov/30051972/)
- [The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Front Endocrinol (Lausanne), 2026](https://pubmed.ncbi.nlm.nih.gov/42395176/)
- [Detection of GHRP-2 and GHRP-6 in urine samples from athletes — Drug Test Anal, 2015](https://pubmed.ncbi.nlm.nih.gov/25809000/)
- [Pharmacotherapy in Cachexia: A Review of Endocrine Abnormalities and Steroid Pharmacotherapy — J Pain Palliat Care Pharmacother, 2022](https://pubmed.ncbi.nlm.nih.gov/35758863/)
